Tech Company Financing Transactions
LongBio Funding Round
Qiming Ventures and private investors joined a Series B funding round for LongBio. The round was recorded on 9/24/2024.
Transaction Overview
Company Name
Announced On
9/24/2024
Transaction Type
Venture Equity
Amount
Unknown
Round
Series B
Investors
Qiming Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance late-stage clinical studies in its pipeline, strengthen team capabilities, and bolster working capital.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
No. 88 building, #887 Zuchongzhi road, Zhangjiang Hi-tech Pa 302
Shanghai, Undisclosed
China
Shanghai, Undisclosed
China
Phone
Undisclosed
Website
Email Address
Overview
LongBio Pharma is a biotech company located in Shanghai, China. The company, which was founded in 2018, is focused on autoimmune and rare diseases, serving patients and society. The co-founder of LongBio Pharma, Dr. Sun, Bill, Nai-chau, is also the co-founder of Tanox, with its IPO in Nasdaq at 2000 and acquired by Genentech in 2007. He is also the co-inventor of Omalizumab (Xolair®, Global sales is 3.6B USD in 2022), the first anti-IgE antibody approved by FDA.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Medical Officer
Jay Lou
Co-Founder
Heng Heng
Co-Founder
Bill Sun
Browse more venture capital transactions:
Prev: 9/24/2024: VerImmune venture capital transaction
Next: 9/24/2024: LiveFlow venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs